- €771.69m
- €704.43m
- $376.13m
Europe Research Roundup: Heineken NV, Integrafin Holdings Plc, Kingfisher
Pharming Group jumps after it hikes Ruconest revenues guidance
Brief: Pharming Group 2023 Preliminary Revenue at USD 245 Million
Brief: Pharming Group Announces Updated Full Year 2023 Guidance And Joenja U.S. Launch Update
Development Plans For Leniolisib For Additional Primary Immunodeficiencies
Brief: Pharming Announces Development Plans For Leniolisib For Additional Primary Immunodeficiencies
Brief: Pharming Group updates on EMA regulatory review of leniolisib MAA
Brief: Pharming Group Reports Third Quarter 2023 Financial Results
Competition and Mkts - CMA update: Arcelik / Whirlpool
Dr. Peters Becomes Chair Of Board Of Directors
'Interesting times ahead' - Van Lanschot upgrades Pharming to 'buy'
Brief: Pharming Group Says First Patient Enrolled in Phase III Clinical Trial Of Leniolisib For The Treatment Of APDS In Japan
Brief: Pharming Group H1 Revenues Up 1% To $97.4 Mln
Brief: Pharming Sells Priority Review Voucher To Novartis
Brief: Pharming Group Q1 Revenue Down to USD 42.5 Mln
Brief: Pharming Group Q1 Revenue at USD 42.5 Million
Brief: Pharming Group's First Commercial Sale Of Joenja Triggers A $10 Mln Milestone Payment To Novartis
RBC starts Pharming at 'outperform' after leniolisib FDA approval
Pharming Group set for best day in nearly 3 yrs after FDA approves immune disorder drug